Conformal radiotherapy for hepatocellular carcinoma

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 2, 2008, Pages 113-123

  Tse, R V ^a   Guha, Chandan ^b   Dawson, L A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Conformal radiotherapy; Hepatocellular carcinoma; Proton therapy; Radiation induced liver disease (RILD); Radiotherapy; Stereotactic radiotherapy

Indexed keywords

TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

CANCER INCIDENCE; CANCER RECURRENCE; CHEMOEMBOLIZATION; EXTERNAL BEAM RADIOTHERAPY; HEAVY ION RADIATION; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROTON THERAPY; RADIATION DOSE; RADIATION INDUCED LIVER DISEASE; REVIEW; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; VEIN OCCLUSION;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HEAVY IONS; HUMANS; LIVER; LIVER NEOPLASMS; PROTONS; RADIOSURGERY; RADIOTHERAPY, CONFORMAL;

EID: 45949100612     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.01.005     Document Type: Review

References (87)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 10 (1999) 745-750
3. American Cancer Society. Cancer Facts and Figures 2007 (2007), American Cancer Society, Atlanta, Ga
4. Beasley R.P., Hwang L.Y., Lin C.C., and Chien C.S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 2 8256 (1981) 1129-1133
5. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on Hepatitis B Virus and Cirrhosis. Hepatology 21 1 (1995) 77-82
6. Liaw Y.F., Tai D.I., Chu C.M., et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 90 2 (1986) 263-267
7. Bruno S., Silini E., Crosignani A., et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 25 3 (1997) 754-758
8. Tsukuma H., Hiyama T., Tanaka S., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328 25 (1993) 1797-1801
9. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., and Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313 20 (1985) 1256-1262
10. Choi T.K., Edward C.S., Fan S.T., Francis P.T., and Wong J. Results of surgical resection for hepatocellular carcinoma. Hepato-Gastroenterology 37 2 (1990) 172-175
11. Nagorney D.M., van Heerden J.A., Ilstrup D.M., and Adson M.A. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 106 4 (1989) 740-748
12. Kuvshinoff B.W., and Ota D.M. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 132 4 (2002) 605-611
13. Solbiati L., Livraghi T., Goldberg S.N., et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221 1 (2001) 159-166
14. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 5 (2002) 1164-1171
15. Camma C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 1 (2002) 47-54
16. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 2 (2003) 429-442
17. Yeo W., Mok T.S., Zee B., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 20 (2005) 1532-1538
18. Leung T.W., Patt Y.Z., Lau W.Y., et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5 7 (1999) 1676-1681
19. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 26 (2006) 4293-4300
20. Eccles C., Brock K.K., Bissonnette J.P., Hawkins M., and Dawson L.A. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys 64 3 (2006) 751-759
21. Lawrence T.S., Robertson J.M., Anscher M.S., Jirtle R.L., Ensminger W.D., and Fajardo L.F. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31 5 (1995) 1237-1248
22. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18 11 (2000) 2210-2218
23. Cheng J.C., Wu J.K., Lee P.C., et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60 5 (2004) 1502-1509
24. Yamasaki S.A., Marn C.S., Francis I.R., Robertson J.M., and Lawrence T.S. High-dose localized radiation therapy for treatment of hepatic malignant tumors: CT findings and their relation to radiation hepatitis. AJR Am J Roentgenol 165 1 (1995) 79-84
25. Sempoux C., Horsmans Y., Geubel A., et al. Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology 26 1 (1997) 128-134
26. Anscher M.S., Crocker I.R., and Jirtle R.L. Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res 122 1 (1990) 77-85
27. Chou C.H., Chen P.J., Lee P.H., Cheng A.L., Hsu H.C., and Cheng J.C. Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells. Clin Cancer Res 13 3 (2007) 851-857
28. Geraci J.P., Mariano M.S., and Jackson K.L. Hepatic radiation injury in the rat. Radiat Res 125 1 (1991) 65-72
29. Guha C., Yamanouchi K., Jiang J., et al. Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias. Am J Nephrol 25 2 (2005) 161-170
30. Cromheecke M., Vermeij J., Grond A.J., Konings A.W., Oldhoff J., and Hoekstra H.J. Tissue tolerance of normal and surgically manipulated canine liver to intraoperative radiation therapy (IORT). Int J Radiat Oncol Biol Phys 27 5 (1993) 1141-1146
31. Epstein R.B., Min K.W., Anserson S.L., and Syzek L. A canine model for hepatic venoocclusive disease. Transplantation 54 1 (1992) 12-16
32. Stephens L.C., Peters L.J., and Ang K.K. Tolerance of rhesus monkey liver to ionizing radiation. Radiat Oncol Invest 1 (1994) 279-284
33. Maj J.G., Paris F., Haimovitz-Friedman A., Venkatraman E., Kolesnick R., and Fuks Z. Microvascular function regulates intestinal crypt response to radiation. Cancer Res 63 15 (2003) 4338-4341
34. Guha C., Sharma A., Gupta S., et al. Amelioration of radiation-induced liver damage in partially hepatectomized rats by hepatocyte transplantation. Cancer Res 59 23 (1999) 5871-5874
35. Seong J., Kim S.H., Chung E.J., Lee W.J., and Suh C.O. Early alteration in TGF-beta mRNA expression in irradiated rat liver. Int J Radiat Oncol Biol Phys 46 3 (2000) 639-643
36. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 1 (1991) 109-122
37. Ingold J.A., Reed G.B., and Kaplan H.S. Radiation hepatitis. Am J Roentgenol 93 (1965) 200-208
38. Austin-Seymour M.M., Chen G.T., Castro J.R., et al. Dose volume histogram analysis of liver radiation tolerance. Int J Radiat Oncol Biol Phys 12 1 (1986) 31-35
39. Kutcher G.J., and Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 16 6 (1989) 1623-1630
40. Dawson L.A., Normolle D., Balter J.M., McGinn C.J., Lawrence T.S., and Ten Haken R.K. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53 4 (2002) 810-821
41. Ben-Josef E., Normolle D., Ensminger W.D., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 23 34 (2005) 8739-8747
42. Liang S.X., Zhu X.D., Xu Z.Y., et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65 2 (2006) 426-434
43. Mornex F., Girard N., Beziat C., et al. Feasibility and efficacy of high-dose three-dimensional radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 66 4 (2006) 1152-1158
44. Aoki K., Okazaki N., Okada S., et al. Radiotherapy for hepatocellular carcinoma: clinicopathological study of seven autopsy cases. Hepato-Gastroenterology 41 5 (1994) 427-431
45. Park H.C., Seong J., Han K.H., Chon C.Y., Moon Y.M., and Suh C.O. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 54 1 (2002) 150-155
46. Seong J., Park H.C., Han K.H., and Chon C.Y. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 55 2 (2003) 329-336
47. Seong J., Shim S.J., Lee I.J., Han K.H., Chon C.Y., and Ahn S.H. Evaluation of the prognostic value of Okuda, cancer of the liver Italian program, and Japan integrated staging systems for hepatocellular carcinoma patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys 67 4 (2007) 1037-1042
48. Park W., Lim D.H., Paik S.W., et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 61 4 (2005) 1143-1150
49. Liu M.T., Li S.H., Chu T.C., et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 34 9 (2004) 532-539
50. Kim T.H., Kim D.Y., Park J.W., et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 29 6 (2006) 568-575
51. Lax I., Blomgren H., Naslund I., and Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33 6 (1994) 677-683
52. Blomgren H., Lax I., NAslund I., and Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 34 6 (1995) 861-870
53. Blomgren H., Lax I., Goranson H., et al. Radiosurgery for tumors in the body: clinical experience using a new method. J Radiosurg 1 1 (1998) 63-74
54. Herfarth K.K., Debus J., Lohr F., et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19 1 (2001) 164-170
55. Wulf J., Guckenberger M., Haedinger U., et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncolog 45 7 (2006) 838-847
56. Mendez Romero A., Wunderink W., Hussain S.M., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol. 45 7 (2006) 831-837
57. Tse R.V., Hawkins M., Lockwood G., Kim J.J., Cummings B., and Knox J. Phase I study of stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 26 4 (2008) 657-664
58. Hsu H.C., Wei T.C., Tsang Y.M., Wu M.Z., Lin Y.H., and Chuang S.M. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer 57 6 (1986) 1184-1191
59. Zeng Z.C., Tang Z.Y., Fan J., et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 10 5 (2004) 307-316
60. Wu D.H., Liu L., and Chen L.H. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. W J Gastroenterol 10 15 (2004) 2184-2189
61. Guo W.J., Yu E.X., Liu L.M., et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 9 8 (2003) 1697-1701
62. Cheng J.C., Chuang V.P., Cheng S.H., et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 47 2 (2000) 435-442
63. Koike Y., Nakagawa K., Shiratori Y., et al. Factors affecting the prognosis of patients with hepatocellular carcinoma invading the portal vein-a retrospective analysis using 952 consecutive HCC patients. Hepato-Gastroenterology 50 54 (2003) 2035-2039
64. Fujii T., Takayasu K., Muramatsu Y., et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 23 2 (1993) 105-109
65. Yamada K., Soejima T., Sugimoto K., et al. Pilot study of local radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Jpn J Clin Oncol 31 4 (2001) 147-152
66. Yamada K., Izaki K., Sugimoto K., et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 57 1 (2003) 113-119
67. Ishikura S., Ogino T., Furuse J., et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 25 2 (2002) 189-193
68. Zeng Z.C., Fan J., Tang Z.Y., et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 61 2 (2005) 432-443
69. Lin C.S., Jen Y.M., Chiu S.Y., et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 36 4 (2006) 212-217
70. Bush D.A., Hillebrand D.J., Slater J.M., and Slater J.D. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 127 5 Suppl 1 (2004) S189-S193
71. Chiba T., Tokuuye K., Matsuzaki Y., et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 11 10 (2005) 3799-3805
72. Hata M., Tokuuye K., Sugahara S., et al. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 107 3 (2006) 591-598
73. Hata M., Tokuuye K., Sugahara S., et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 104 4 (2005) 794-801
74. Tokuuye K., Akine Y., Hashimoto T., et al. Proton beam therapy alone for hepatocellular carcinoma. ASCO Gastrointestinal Cancer Symposium (2005) [Abstract 132]
75. Kato H., Tsujii H., Miyamoto T., et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 59 5 (2004) 1468-1476
76. Llovet J., Ricci S., Mazzaferro V., et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol [Meeting Abstracts] 25 18S (2007) LBA1
77. Schwartz J.D., Schwartz M., Lehrer D., et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol [Meeting Abstracts] 24 18 S (2006) 4144
78. Hewitt M.R., Sun W., Haller D.G., et al. A phase II trial of combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): preliminary safety analysis. J Clin Oncol [Meeting Abstracts] 24 18S (2006) 14098
79. Liao Z., Komaki R., Milas L., et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11 9 (2005) 3342-3348
80. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
81. Moon W.S., Rhyu K.H., Kang M.J., et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?. Mod Pathol 16 6 (2003) 552-557
82. Dhar D.K., Naora H., Yamanoi A., et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res 22 1A (2002) 379-386
83. Sugimachi K., Tanaka S., Taguchi K., Aishima S., Shimada M., and Tsuneyoshi M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 56 11 (2003) 854-860
84. Chen L., Yang Z., Wang G., Wang C., et al. Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma. J Tongji Med Univ 21 3 (2001) 228-230
85. Mitsuhashi N., Shimizu H., Ohtsuka M., et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37 5 (2003) 1105-1113
86. Kawakita T., Shiraki K., Yamanaka Y., et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 318 3 (2004) 726-733
87. Torimura T., Ueno T., Kin M., et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 40 5 (2004) 799-807